logo

Provention Bio, Inc. (PRVB)



Trade PRVB now with
  Date
  Headline
5/20/2020 7:14:34 AM Provention Bio Names Nancy Wysenski As A New Director; Anthony DiGiandomenico Steps Down
5/18/2020 7:04:36 AM Provention Bio And Vactech Publish Proof-of-Concept Data For Preclinical Prototype Of Coxsackievirus B Vaccine
4/16/2020 7:08:50 AM Provention Bio Initiates Rolling Submission Of BLA For Teplizumab
3/12/2020 7:09:20 AM Provention Bio FY Net Loss $43.3 Mln Or $1.06/Shr Vs Loss Of $26.8 Mln Or $1.19/Shr Last Year
3/12/2020 7:05:47 AM Provention Announces Top-line Results From Phase 1b PREVAIL Study Of PRV-3279
1/8/2020 7:07:23 AM Provention Bio Appoints Jason Hoitt As Chief Commercial Officer
10/24/2019 8:19:50 AM Provention Bio Announces EMA Grants PRV-031 PRIME Designation
10/22/2019 7:23:33 AM Provention Bio Says Phase 2a PRINCE Clinical Trial Did Not Achieve Primary Endpoint
9/26/2019 7:05:38 AM Provention Bio Appoints Sean Doherty To Board
9/18/2019 8:41:09 PM Provention Bio. Prices Underwritten Registered Public Offering Of 5 Mln Shares At $8.00/shr
9/18/2019 4:18:42 PM Provention Bio Announces Proposed Public Offering Of Common Stock
8/20/2019 7:07:30 AM Provention Bio Appoints Sherron Kell As SVP Of Clinical Development
8/6/2019 7:37:46 AM Provention Bio Q2 Net Loss $12.0 Mln Or $0.32/shr Vs. Net Loss $10.5 Mln Or $1.05/shr Prior Year
8/5/2019 7:26:18 AM Provention Bio Says Breakthrough Therapy Designation For Teplizumab For Prevention Or Delay Of Clinical Type 1 Diabetes